Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Down 57.7% in January

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 1,303 shares, a decrease of 57.7% from the January 15th total of 3,079 shares. Based on an average daily volume of 8,921 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s stock are sold short. Currently, 0.1% of the company’s stock are sold short. Based on an average daily volume of 8,921 shares, the short-interest ratio is presently 0.1 days.

Global X Genomics & Biotechnology ETF Stock Down 1.8%

Shares of NASDAQ GNOM traded down $0.84 during midday trading on Thursday, reaching $45.32. 5,886 shares of the company’s stock traded hands, compared to its average volume of 9,582. The company has a market cap of $49.40 million, a price-to-earnings ratio of -19.37 and a beta of 1.22. The stock’s 50 day simple moving average is $47.28 and its 200-day simple moving average is $42.55. Global X Genomics & Biotechnology ETF has a one year low of $27.20 and a one year high of $51.42.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were given a dividend of $0.5912 per share. This represents a yield of 259.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is -26.50%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A number of hedge funds have recently made changes to their positions in GNOM. IFP Advisors Inc boosted its stake in Global X Genomics & Biotechnology ETF by 20.8% in the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after acquiring an additional 489 shares in the last quarter. Creative Financial Designs Inc. ADV raised its stake in Global X Genomics & Biotechnology ETF by 4.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after buying an additional 481 shares during the last quarter. U.S. Capital Wealth Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter worth about $575,000. Atria Investments Inc boosted its holdings in Global X Genomics & Biotechnology ETF by 12.6% in the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after acquiring an additional 2,073 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the last quarter. 56.95% of the stock is currently owned by hedge funds and other institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.